Tanım

Human papillomavirus infection (HPV infection) is caused by a DNA virus from the Papillomaviridae family. Many HPV infections cause no symptoms and 90% resolve spontaneously within two years. Available HPV vaccines protect against either two, four, or nine types of HPV. All HPV vaccines protect against at least HPV types 16 Ve 18, which cause the greatest risk of cervical cancer. It is estimated that HPV vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and show more than 90% efficacy in preventing HPV-positive oropharyngeal cancers. A study by StrategyHelix indicates that the global human papillomavirus market is expected to increase by US$ 2.5 billion from 2022 ile 2028, garnering a CAGR of 6.4% tahmin dönemi boyunca.

Rapor, döneme ilişkin güncel pazar büyüklüğü verilerini sağlar 2018-2021 ve tahmin 2028 covering key market aspects like sales value for human papillomavirus. The global human papillomavirus market is segmented on the basis of type, dosage, başvuru, age, end user, ve bölge. Türe göre, the global human papillomavirus market is categorized into bivalent HPV vaccine (2vHPV), quadrivalent HPV vaccine (4vHPV), 9-valent HPV vaccine (9vHPV). On the basis of dosage, the global human papillomavirus market has been segmented into 2 dose, 3 dose. By application, the global human papillomavirus market has been segmented into HPV-attributable cancer, genital warts. Based upon age, the global human papillomavirus market is categorized into under 15 yıllar, 15 ile 45 yıllar. On the basis of end user, the global human papillomavirus market has been segmented into community clinics, doctor’s office, health departments, hospitals, school-based health centers, diğerleri. In terms of geography, the global human papillomavirus market has been segmented into Asia Pacific, Avrupa, Kuzey Amerika, Dünyanın Geri Kalanı (RoW).

The global human papillomavirus market is highly competitive. The key players in the human papillomavirus market include Beijing Health Guard Biotechnology Inc., Beijing Wantai Biopharmaceutical Co. Ltd., BioLeaders Corporation, GSK plc, Inovio Pharmaceuticals Inc., Merck & ortak. Inc., R-Pharm Group, Sanofi S.A., Serum Institute of India Pvt. Ltd., Vaccitech plc, Walvax Biotechnology Co. Ltd.. Competitive landscape gives a description of the competitive nature of the global human papillomavirus market and a description of the leading companies. Son yıllarda piyasayı şekillendiren önemli finansal anlaşmalar belirlendi.

Rapor, bu sektörde faaliyet gösteren şirket ve kuruluşlar için paha biçilmez bir kaynaktır. It provides a cohesive picture of the human papillomavirus market to help drive informed decision making for industry executives, kural koyucular, akademik, ve analistler.

Rapor Kapsamı

Tip: bivalent HPV vaccine (2vHPV), quadrivalent HPV vaccine (4vHPV), 9-valent HPV vaccine (9vHPV)
Dosage: 2 dose, 3 dose
Başvuru: HPV-attributable cancer, genital warts
Age: under 15 yıllar, 15 ile 45 yıllar
End user: community clinics, doctor’s office, health departments, hospitals, school-based health centers, diğerleri
Bölge: Asya Pasifik, Avrupa, Kuzey Amerika, Dünyanın Geri Kalanı (RoW)
Dikkate alınan yıllar: bu rapor dönemi kapsamaktadır 2018 ile 2028
Adı geçen şirket: Beijing Health Guard Biotechnology Inc., Beijing Wantai Biopharmaceutical Co. Ltd., BioLeaders Corporation, GSK plc, Inovio Pharmaceuticals Inc., Merck & ortak. Inc., R-Pharm Group, Sanofi S.A., Serum Institute of India Pvt. Ltd., Vaccitech plc, Walvax Biotechnology Co. Ltd..

Paydaşlar için Temel Faydalar

– Get a comprehensive picture of the global human papillomavirus market
– Yerel verilere dayanarak bölgesel stratejiler ve stratejik önceliklerin belirlenmesi
– Büyüme sektörlerini ve yatırım eğilimlerini belirleyin

İçindekiler

Parça 1. giriiş
– Çalışmanın kapsamı
– Çalışma periyodu
– Coğrafik kapsam
– Araştırma metodolojisi
Parça 2. Human papillomavirus market overview
Parça 3. Market breakdown by type
– Bivalent HPV vaccine (2vHPV)
– Quadrivalent HPV vaccine (4vHPV)
– 9-valent HPV vaccine (9vHPV)
Parça 4. Market breakdown by dosage
– 2 dose
– 3 dose
Parça 5. Market breakdown by application
– HPV-attributable cancer
– Genital warts
Parça 6. Market breakdown by age
– Under 15 yıllar
– 15 ile 45 yıllar
Parça 7. Market breakdown by end user
– Community clinics
– Doctor’s office
– Health departments
– Hastaneler
– School-based health centers
– Diğerleri
Parça 8. Market breakdown by region
– Asya Pasifik
– Avrupa
– Kuzey Amerika
– Dünyanın Geri Kalanı (RoW)
Parça 9. Anahtar şirketler
– Beijing Health Guard Biotechnology Inc.
– Beijing Wantai Biopharmaceutical Co., Ltd..
– BioLeaders Corporation
– GSK plc
– Inovio Pharmaceuticals, A.Ş..
– Merck & Şti., A.Ş..
– R-Pharm Group
– Sanofi SA.
– Serum Institute of India Pvt. Ltd..
– Vaccitech plc
– Walvax Biotechnology Co., Ltd..
StratejiHelix Hakkında
Sorumluluk reddi beyanı